ARID1A deficiency is targetable by AKT inhibitors in HER2-negative gastric cancer

ConclusionsThe effect of AKT inhibitors on cell proliferation and survival is affected by HER2 status, providing a rationale for exploring targeted therapy using AKT inhibitors in ARID1A-deficient/HER2-negative GC.

Source: Gastric Cancer - February 22, 2023 Category: Gastroenterology Source Type: research